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Abstract
Rationale Poor cognitive control, including reversal learn-
ing deficits, has been reported in children with attention
deficit hyperactivity disorder, in stimulant-dependent
humans, and in animal models of these disorders; these
conditions have each been associated with abnormal
catecholaminergic function within the prefrontal cortex.
Objectives In the current studies, we sought to explore how
elevations in extracellular catecholamine levels, produced
by pharmacological inhibition of catecholamine reuptake
proteins, affect behavioral flexibility in rats and monkeys.
Materials and methods Adult male Long–Evans rats and
vervet monkeys were trained, respectively, on a four-
position discrimination task or a three-choice visual
discrimination task. Following systemic administration of
pharmacological inhibitors of the dopamine and/or norepi-
nephrine membrane transporters, rats and monkeys were
exposed to retention or reversal of acquired discriminations.
Results In accordance with our a priori hypothesis, we
found that drugs that inhibit norepinephrine transporters,
such as methylphenidate, atomoxetine, and desipramine,
improved reversal performance in rats and monkeys; this
was mainly due to a decrease in the number of persevera-
tive errors. Interestingly, the mixed dopamine and norepi-
nephrine transporters inhibitor methylphenidate, if
anything, impaired performance during retention in both
rats and monkeys, while administration of the selective
dopamine transporter inhibitor GBR-12909 increased pre-
mature responses but did not alter reversal learning
performance.
Conclusions Our results suggest that pharmacological
inhibition of the membrane norepinephrine, but not mem-
brane dopamine, transporter is associated with enhanced
behavioral flexibility. These data, combined with earlier
reports, may indicate that enhanced extracellular catechol-
amine levels in cortical regions, secondary to norepineph-
rine reuptake inhibition, improves multiple aspects of
inhibitory control over responding in rats and monkeys.
Keywords ADHD . Norepinephrine . Cognition .
Dopamine . Reversal learning . Frontal cortex .
Catecholamine
Introduction
In higher mammals, prefrontal-cortex-dependent executive
functions support behavioral adaptation to a changing
environment by permitting the introduction of flexibility
into responding. Without this top-down cognitive control,
behavior is more likely to be driven by simple sensory
motor associations and habits (depending upon other
cortical and subcortical regions), resulting in automatic
and/or inflexible behavior (Miller and Cohen 2001).
Laboratory tasks, such as discrimination reversal learn-
ing, have been used in both human and animal subjects to
study aspects of executive control and behavioral flexibility
(Ragozzino 2007; Robbins 2007; Roberts and Wallis 2000).
In related procedures, the associations between stimuli and
outcomes are learnt by a subject before being unexpectedly
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reversed by the experimenter; after reversal, subjects have
to alter their behavioral repertoire in order to discover the
predictors of reward and/or to avoid a punishment. This
may require the subject to stop pre-potent or conditioned
responses (i.e., response inhibition) and/or overcome the
learned irrelevance for the alternative responses (Clarke
et al. 2007; Tait and Brown 2007), while the generation of
new behaviors may arise by the intervention of others
executive processes, such as working memory and/or
response selection (Frank and Claus 2006; Miller and
Cohen 2001).
Previous studies have shown that damage to the
orbitofrontal cortex produces a selective reversal learning
deficit (Boulougouris et al. 2007; Dias et al. 1996; Hornak
et al. 2004; Iversen and Mishkin 1970; McAlonan and
Brown 2003; Rolls et al. 1994; Schoenbaum et al. 2002),
along with poor response inhibition (Aron et al. 2003b;
Eagle et al. 2008), while damage to other prefrontal regions
impairs behavioral flexibility only when the updating of
attentional biases or rules is required (Birrell and Brown
2000; Dias et al. 1996; Owen et al. 1991; Ragozzino and
Kesner 2001).
These phenomena appear to be of clinical relevance, as
reversal learning deficits and/or response inhibition deficits
have been reported in children with attention deficit
hyperactivity disorder (ADHD; Itami and Uno 2002;
Schachar et al. 2000, 1995), in stimulant-dependent humans
(Fillmore and Rush 2002, 2006; Monterosso et al. 2005), or
in animal models exposed chronically to addictive psycho-
stimulant drugs (Calu et al. 2007; Jentsch et al. 2002).
These conditions have each been empirically or theoreti-
cally associated with abnormal orbito-prefrontal functions
(Everitt et al. 2007; Hesslinger et al. 2002; Olausson et al.
2007; Schoenbaum and Shaham 2008).
Ascending catecholaminergic systems are involved in
the regulation of frontal-cortex-related executive functions
(Arnsten and Li 2005; Robbins 2005), and clinical data
related to the effective treatment of ADHD point to these
systems as a potential target for the modulation of response
inhibition and cognitive control. Stimulant drugs, such as
methylphenidate (MPH), are common medications for
ADHD and are known to inhibit norepinephrine and
dopamine transporters (NET and DAT, respectively;
Bymaster et al. 2002; Han and Gu 2006), increasing the
extracellular levels of these catecholamines in different
cortical and subcortical regions (Berridge et al. 2006;
Bymaster et al. 2002; Kuczenski and Segal 1997). A large
amount of data suggest a beneficial effects of these drugs
on different domains of executive control, including
behavioral inhibition, in both ADHD patients (Aron et al.
2003a; Scheres et al. 2003; Tannock et al. 1989; Willcutt et
al. 2005) and animal models (Arnsten and Dudley 2005;
Berridge et al. 2006; Blondeau and Dellu-Hagedorn 2007;
Eagle et al. 2007; Lapiz et al. 2007; Navarra et al. 2008;
Robinson et al. 2008).
Although these beneficial effects of stimulant drugs, as
well as their abuse liability (that make them problematic for
the treatment of stimulant abuse and dependence; Volkow
and Swanson 2003), have been attributed to their dopami-
nergic actions, new evidence strongly suggests that the
modulation of noradrenergic system may be relevant as
well. In fact, the selective NET inhibitor atomoxetine
(ATO) has been shown to be an effective alternative to
stimulant drugs in ADHD treatment (Faraone et al. 2005;
Spencer et al. 2001), and recent data have shown that this
drug improves response inhibition in ADHD patients
(Chamberlain et al. 2007), healthy subjects (Chamberlain
et al. 2006), and in experimental animals (Blondeau and
Dellu-Hagedorn 2007; Navarra et al. 2008; Robinson et al.
2008), suggesting that the inhibition of the NET alone may
improve cognitive control.
In the current study, we compared the actions of drugs
selective for each of the two catecholamine transporters,
with MPH, in reversal learning tasks designed to measure
aspect of cognitive control and flexible responding in
rodents and non-human primates. We exposed rats to serial
retentions and reversals of a four-choice spatial discrimina-
tion task, and we tested the effect of the administration of
the stimulant drug MPH, the selective DAT inhibitor GBR-
12909 (GBR), and the selective NET inhibitors ATO and
desipramine (DMI). Monkeys performing a three-choice
discrimination task that included two different sets of visual
discriminanda were also used to examine the effects of a
subset of these agents. We predicted that by virtue of NET
inhibition, MPH, ATO, and DMI would improve perfor-
mance selectively under reversal condition, while GBR
would not. By employing three- and four-choice tasks in
monkeys and rats, respectively, we were able to examine
the patterns of errors made by subjects in order to dissociate
perseverative errors (i.e., responses to the previous
rewarded hole) from neutral errors (i.e., responses to the
other incorrect holes), clarifying whether changes in
reversal learning performance could be attributed to the
ability to change the initially trained response (i.e., response
inhibition).
Materials and methods
Subjects
Sixty-one adult male Long–Evans rats (Harlan, Indianapolis,
IN, USA) were used in these experiments. The subjects
were ~60 days of age at the initiation of training and
ranged in weight from 300 to 400 g during the
experimental period. All rats were initially food-restricted
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to 80–85% of their free-feeding weights and subsequently
fed ~15 g rat chow per day in their home cage within 1–
3 h after testing. Water was continuously available, except
while in the operant testing chambers. Rats were main-
tained in 14/10-h light/dark schedule (lights on at 7 A.M.).
In addition, four male vervet monkeys (Chlorocebus
aethiops sabaeus) from the UCLAVervet Research Colony
were included in the experiments; they were 9–11 years of
age and weighed 6.0–8.0 kg at the time of testing. The
monkeys were housed individually in a climate-controlled
vivarium on a 12-h light/dark cycle (lights on at 6 A.M.);
they had unlimited access to water and received a
nutritionally balanced diet of monkey chow (Teklad,
Madison WI, USA) supplemented with fresh fruit. The
monkeys received their full daily allotment of food (which
was not reduced in order to support behavioral perfor-
mance) immediately after morning testing (one half
portion) and again at 1600–1700 hours (one half portion).
The experimental protocols employed were consistent
with the NIH “Guide for the Care and Use of Laboratory
Animals” and were approved by the Chancellor’s Animal
Research Committee at UCLA. All methods for the care
and use of nonhuman primates conformed to US Department
of Agriculture and Public Health Service standards.
Drugs
For the rat studies, doses of atomoxetine hydrochloride
(1.0 mg/kg, gift from Pfizer) and desipramine hydrochlo-
ride (5.0 mg/kg; Sigma-Aldrich; St Louis, MO, USA) were
chosen on the basis of a pilot study with a two-choice
variant of the task described here (Seu and Jentsch 2006).
Doses of methylphenidate hydrochloride (0.33–1.0 mg/kg;
Sigma-Aldrich) and GBR-12909 dihydrochloride (2.5–
5 mg/kg; Sigma-Aldrich) were chosen based upon previous
studies showing relevant effects of this drugs in other
behavioral procedures that measure inhibitory control in
rats (Eagle et al. 2007; van Gaalen et al. 2006a).
All drugs were dissolved in sterile saline (0.9%) and
were administered in a volume of 1.0 ml/kg, with the
exception of GBR-12909 that was administered in a
volume of 2.0 ml/kg. Methylphenidate, GBR-12909, and
desipramine were injected 30 min before testing, while
atomoxetine was administered 45 min prior to testing.
For the monkey studies, doses of atomoxetine (1 mg/kg;
Tocris-Cookson; Ellisville, MO, USA) and methylpheni-
date (0.33 mg/kg; Sigma-Aldrich) were selected on the
basis of pilot studies in which two different doses were
tested on the same subjects but using a slightly different
reversal learning task. We chose to administer all drugs by
oral delivery rather than via intramuscular injections for the
reason that we expected such route of administration to be
better comparable with clinical studies. Drugs were mixed
with fruit jam or peanut butter and put in a small cookie.
Before every acquisition session, a cookie with jam or
peanut butter (but without drug) was given to the subjects
to avoid the fact that the cookie might be recognized as cue
for the subsequent retention or reversal session. Drugs were
administered 1 h before the retention or reversal sessions,
and the experimenter assured whether the cookie and jam
were eaten or not.
Rat behavioral testing apparatus
Standard extra-tall aluminum and Plexiglas operant condi-
tioning chambers with a photocell-equipped pellet delivery
magazine on one side and a curved panel with five
photocell-equipped apertures on the opposite side (Med
Associates, Mount Vernon, VT, USA) were used. The
boxes were housed inside a sound-attenuating cubicle,
background white noise was broadcasted, and the environ-
ment was illuminated with a houselight (a light diffuser that
was located outside of the operant chamber but within the
cubicle).
Rat training
Most of the prior reversal learning studies described in
rodents and monkeys have been conducted using two-
choice discrimination tasks (Boulougouris et al. 2007; Dias
et al. 1996; Iversen and Mishkin 1970; McAlonan and
Brown 2003; Schoenbaum et al. 2002). We chose to adopt a
novel four-choice task in order to increase general task
difficulty and to permit us to dissect perseverative from
neutral errors.
The procedure for the initial training was similar to that
used for a lateralized reaction time task (Jentsch 2003). Rats
were first trained in a single session in which the houselight
was continuously illuminated and single pellets (45 mg
Dustless Precision Pellets; Bio-serv, Frenchtown, NJ, USA)
were delivered into an illuminated magazine on a fixed-
time 20-s schedule over a 45-min period. Across three
subsequent daily sessions, the rats were then trained to
make a sustained, variable duration nose poke (200, 500,
700, or 1,000 ms) in an illuminated center nose poke
aperture (hole 3) to receive a pellet. This response (called
the observing response) was used in the subsequent
sessions to begin a new trial in order to demonstrate task
engagement and to avoid random responding. All rats were
trained until they earned at least 70–80 pellets in this initial
shaping component.
The rats were then tested in daily discrimination sessions
in which the initiation of individual trials was signaled by
the illumination of the central aperture. A variable-duration
observing response at that location resulted in the imme-
diate switching off of the central light and illumination of
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the four remaining apertures, two to the left of the central
aperture (holes 1 and 2; H1 and H2) and two to the right
(holes 4 and 5; H4 and H5). On any given day, one of the
holes was chosen by the experimenter to be the target hole,
and rats were reinforced with a pellet for a response into
that hole only (correct response). Importantly, no signal,
other than reinforcement feedback, indicated which of the
four holes was the target on any given day.
If the rat responded at a location that was not the
established target, all lights in the box were extinguished,
and the rat was given a 3-s time-out period in complete
darkness (incorrect response). If no response was made
within 15 s, the rat received a 3-s time-out in darkness
(omission). The inter-trial interval that followed a completed
trial or omission was 3 s. On occasion, rats responded into
one of the lateral apertures before completing the sustained
nose poke (and before the target presentation); in this case, a
3-s time-out was delivered (as above), and an anticipatory
response was scored.
Sessions were terminated when rats reached criteria of
18 correct responses in 20 consecutive trials, after 1 h or
when 200 trials were completed, whichever came first. If
rats failed to achieve criterion performance in 1 h or 200
trials, the discrimination was repeated on subsequent days
until criterion was met.
The subjects were exposed to approximately 1 month of
initial training. During this time, rats were tested every 2 to
4 days for an average of 12 discrimination sessions
(including one to two retention sessions), with each of the
four holes assigned as target locations at least twice.
Rat testing—experimental design
After initial training, rats were tested for 2 days a week in
pairs of experimental sessions. During the first session,
referred to as the “new-hole session”, an aperture was
selected pseudorandomly. In the second session, rats were
tested for “retention” of the discrimination learned in the
prior new-hole session (the reinforcement rule was kept
the same) or they were subjected to a “reversal” of the
discrimination learned in the prior new-hole session (a
different aperture was rewarded). Pharmacological treat-
ments were administered only during retention or reversal
sessions, while the new-hole sessions were always per-
formed drug-free.
Note that the new-hole sessions may be considered a
reversal session because the rats are experiencing a change
in the condition learned in the previous session. The new-
hole sessions were used because it seemed to be important
to always test retention or reversal of a discrimination
learned in a drug-free state. This allowed us to ensure that
there were no differences amongst the various drug and
reversal vs. retention conditions in terms of performance in
the immediately preceding session. In addition, a difference
between new-hole and reversal sessions was that more
restrictions were imposed in the choice of the target hole
during reversal sessions in order to simplify the design
and assure the all the conditions within and between drug
studies were balanced. For example, only a switch from
holes positioned on different sides of the central hole
(H5–H1, H5–H2, H4–H2, or H4–H1 and vice versa) was
allowed, while this was not a requirement for new-hole
sessions.
If in a drug study a rat failed to reach performance
criteria in one or more drug sessions, these sessions were
repeated after completion of the formal Latin square design.
However, only one to three rats in each of the drug studies
ever failed to complete a session, and the frequency of
failures never differed between treatment groups.
All rats required at least eight to 12 discrimination
sessions (including retention, reversal, and new-hole ses-
sions) to complete each pharmacological study; considering
initial training and pharmacological testing, each subject
was exposed to 20–40 sessions over the course of the
procedures described in this manuscript.
A minimum of four and a maximum of 14 drug
administrations (of which two to four were saline admin-
istrations) were given to each rat, with an interval between
injections of at least 1 week.
The measures collected during daily sessions included
total number of trials (number of trials required to reach
criterion), the mean trial initiation latency (the average
interval between illumination of the central aperture and
the initiation of the observing response), the mean pellet
retrieval time (the average interval between pellet delivery
and head entry into the magazine), and the number of
anticipatory responses (calculated as a fraction of com-
pleted trials). Omissions were very rare and all drugs
tested failed to affect them, so omissions are not presented
here.
Correct and incorrect responses were measured as
percentage of all completed trials in five-trial bins (trials
1–5, 6–10, etc.). In each study, we analyzed these measures
across the maximum number of trials bins where data
points were present for all rats (because the number of trials
available for analysis depended upon how quickly the rat
reached criteria). For the retention sessions, only four bins
were considered in all drug studies (all experiments
included rats that completed the retention sessions in the
minimum number of trials, i.e., 20), while for the reversal
sessions, the number of bins was variable (between four
and seven).
Furthermore, incorrect responses were defined as
perseverative (i.e., responses to the hole rewarded in the
previous new-hole session) or neutral (responses to the
other two incorrect holes) and were analyzed as a
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percentage of all completed trials in five-trial bins, as
described above.
Monkey behavioral testing apparatus
A modified Wisconsin general test apparatus (WGTA)
consisting of an opaque screen (that could be raised and
lowered) that separated the monkey from a tray fitted with
three opaque square food boxes with hinged opaque lids
was used. The tops of the food boxes were fitted with
distinctive colored pictures (clip art from the Microsoft
Office library), and the monkeys were trained to open the
lids of food boxes to retrieve food rewards (bits of apple,
grape, or banana) hidden within. The monkeys, which had
previously been trained to move voluntarily from their
cages to a transport cart, were moved, one at a time, to an
adjacent testing room. In this room, the transport cart was
aligned to the WGTA so that monkeys could easily access
the food boxes on the tray when the opaque screen was
raised. The monkeys were presented with trials on which
the screen was raised to reveal three food boxes with the
visual cues. They were allowed to open only one box lid
per trial. Each trial lasted either until the animal opened a
lid or 2 min passed, whichever came first. The inter-trial
interval was approximately 15 s. For each set of three visual
cues, the picture that was chosen to be the “positive”
stimulus was varied across the four subjects. The position
of the food boxes varied pseudorandomly across all trials.
Each subject was tested between 8:30 and 11:00 A.M. on
each day.
Monkey testing—reversal learning task
Before the four monkeys participated in this study, they
were trained on a slightly different reversal learning
paradigm and were involved in other pharmacological
studies (Lee et al. 2007). We modified our earlier task
design in an attempt to increase the general difficulty of the
task. Our procedure, like some human discrimination
learning tasks (Frank et al. 2007), involved training subjects
on two separate discriminations, composed of three stimuli
each, within single sessions (discrimination set 1: A,B,C;
discrimination set 2: D,E,F). In every session, half of the
trials included discrimination set 1 and the other half
involved discrimination set 2. The two sets of stimuli were
mixed pseudorandomly across trials; the only constraint on
stimuli presentation order was that the same triad of
pictures was not presented in more than three consecutive
trials. Across daily sessions of 30 trials (15 trials with
stimuli A,B,C and 15 with D,E,F), the monkeys had first to
learn that one stimulus per discrimination was associated
with reward while the others were not (i.e., A+, B−, C− and
D+, E−, F−). Once a minimum criterion of 13 correct
responses out of 15 trials was reached for both sets of
stimuli in a single session, the subjects were tested on the
subsequent day for retention or reversal of the two
discriminations.
The maximum number of acquisition sessions allowed
was four, and when a monkey did not meet this criterion in
four sessions, the testing for that subject was interrupted
and restarted the following week with new sets of stimuli.
However, this circumstance was not very common, and
often, monkeys learned both discriminations within one
session.
The retention and reversal sessions consisted of two
contiguous blocks of 20 trials each consisting of an equal
mix of 10 A-B-C trials and ten D-E-F trials (Fig. 1). In the
retention sessions, the reward contingencies in the two
blocks were the same as in the acquisition sessions (A+,
B−, C− and D+, E−, F−). Differently, in the reversal
sessions, the stimulus–reward associations were changed so
that discrimination set 1 was reversed from the beginning of
the test session (A−, B+, C−), while discrimination set 2
was retained in the first block (D+, E−, F−) and reversed in
the second block (D−, E+, F−). In this way, monkeys were
subjected to two different reversal conditions in the session,
one preceded by a retention test to “prime” responding
(involving discrimination set 2) and one that was not
Fig. 1 Schematic representation of the experimental design used in
the monkey studies. The acquisition sessions consisted of 15 trials for
each set of discriminanda (discrimination 1: A, B, C, disc1;
discrimination 2: D, E, F, disc2) presented in a pseudo-random order.
Once acquisition criterion was achieved, monkeys were tested the
following day on retention or reversal of the two discriminations.
During retention, the contingencies for both set of discriminanda were
the same as in acquisition, while during reversal, one discrimination
set (disc1) was reversed from the beginning of the session and the
other was retained in the block 1 and reversed in block 2
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(involving discrimination set 1). The retention and reversal
sessions were alternated in a pseudorandom way so that no
more than two consecutive weeks included the same
learning conditions.
The measures collected were retention session errors
(total errors committed in the retention sessions), reversal
session retention errors (errors committed during retention
of discrimination set 2 in the first block of the reversal
session), perseverative errors (number of responses to the
previously reinforced stimulus during reversal of discrim-
ination set 1 or 2), neutral errors (number of non
perseverative errors during reversal session), retention
session duration (total time required to complete the
retention session; in s), and reversal session duration (total
time required to complete the reversal session; in s).
Data analysis
All studies were within subjects and the order of drug
conditions counter-balanced (cyclic Latin square design)
across subjects and testing conditions (retention and
reversal).
For the rat experiments, the measures described above
were subjected to repeated measures analysis of variance
(ANOVA), with testing condition, bin, and dose as factors.
Where significant main effects or interactions were
detected, they were further analyzed using a paired two-
tailed t tests. Our a priori hypotheses were tested using
paired one-tailed t tests.
For the monkey studies, specific a priori hypotheses
were examined using one-tailed paired t tests, while for all
the other comparisons, two-tailed paired t tests were used.
Results
Rat studies: baseline performance characteristics
The data collected under saline-only conditions in all the rat
experiments are summarized in Fig. 2 in order to exhibit
baseline performance characteristics of rats performing the
four-choice discrimination task. In retention, rats perform
at ~50% accuracy within the first five trials of the session
(chance performance=25%), reaching ~80% accuracy by
trials 16–20, while under the reversal condition, rats start
out with accuracy which is below chance (Fig. 2a), mainly
due to a tendency to respond toward the previously
rewarded hole (Fig. 2b). Indeed, nearly 50% of the total
responses emitted in the first four bins of the reversal phase
were perseverative (Fig. 2b). Together with this observa-
tion, the analysis of responses to the two “neutral” holes
revealed that performance was guided by a set of long-term
reinforcement rules, incorporating information learned over
many sessions; in fact, rats responded more to the neutral
hole that was rewarded in the most recent session (i.e.,
recent neutral) than to the neutral hole reinforced longest in
the past (i.e., past neutral; Fig. 2b). When considering
accuracy of response during the first four five-trial bins,
ANOVA detected a significant interaction between testing
condition (retention versus reversal) and trial bin [F(1,80)=
3.0, p≤0.05], along with main effects of testing condition
[F(1,80)=228.6, p≤0.0001] and trial bin [F(1,80)=26.7, p≤
0.0001]. A main effect of testing condition was also
observed in the total number of trials required to reach
criterion [F(1,80)=142.1, p≤0.0001] (data not shown).
We ran several analyses in order to evaluate whether
there were differences in the difficulty of performance in
reversal depending upon which hole was being reinforced
in the test session and which hole had been reinforced in
the previous session because it is possible that some
switches were easier than others. During reversal learning
testing, there were no differences in performance (measured
by the total number of trials or proportions of correct,
perseverative, or neutral errors) that were related only to the
current hole being reinforced (all F’s<1). Nevertheless,
Fig. 2 Rat performance in the four-position discrimination task is
illustrated by compiling the saline data collected in all studies. a
Correct responding in the first 20 trials of retention and reversal
sessions (dotted line indicates chance level=25%). b Under reversal
conditions, the majority of incorrect responses were perseverative (i.e.,
responses toward the hole rewarded in the previous session), followed
by recent neutral errors (i.e., responses toward the hole rewarded two
session before) and past neutral errors (i.e., responses to the remaining
hole). Data are expressed as mean percentage±SEM of total responses
in each of the first four five-trial bins of the sessions (n=84)
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ANOVA revealed a main effect of the hole trained in the
previous session when considering the percentage of
responses that were perseverative [F(1,80)=11.2, p≤0.001]
and on total number of trials to meet criteria [F(1,80)=4.1,
p≤0.05]; in fact, when the previous hole was internal (i.e.,
directly adjacent to the hole in which the observing
response was made: H2 and H4), subjects made more
perseverative responses and took more trials to complete
the session. In other words, rats have slightly more
difficulty switching away from the internal holes. However,
all drug conditions were explicitly balanced to control for
the type of reversal sequence being imposed (all drug
treatment conditions were evaluated using an equal number
of shifts from the internal-to-external and external-to-
internal holes).
Experiment 1: differential effects of MPH on the retention
and reversal of a four-choice discrimination
Based upon previous studies showing the beneficial effect
of MPH on aspects of behavioral inhibition (Aron et al.
2003a; Blondeau and Dellu-Hagedorn 2007; Eagle et al.
2007; Navarra et al. 2008; Tannock et al. 1989), we
hypothesized that this drug would improve reversal
performance while not affecting retention performance. As
shown in Fig. 3a, the two doses of MPH tested differently
affected the total number of trials required to reach criteria
in the two testing conditions [dose × testing condition:
F(1,22)=6.1, p≤0.01; dose: F(1,22)=0.4, p=0.69]. Consistent
with our a priori hypothesis, MPH at the dose of 0.33 mg/kg
decreased the total number of trials required to complete the
reversal session (one tailed t test: t=1.7, df=22, p≤0.05);
notably, it increased the total number of trials required to
reach criteria in the retention session (two-tailed t test:
t=−2.8, df=22, p≤0.01). The higher dose of MPH (1 mg/
kg), on the other hand, did not significantly affect the total
number of trial to criteria in either the reversal (one-tailed
t test: t=0.3, df=22, p=0.39) or retention sessions (two-
tailed t test: t=−1.2, df=22, p=0.24).
Neither dose of MPH affected others measures collected,
such as the latency to initiate a trial [dose × testing condition:
F(1,22)=0.8, p=0.46; dose: F(1,22)=1.2, p=0.29], the pellet
retrieval time [dose × testing condition: F(1,22)=0.6, p=0.55
dose: F(1,22)=0.2, p=0.81], or the number of anticipatory
responses made per trial completed [dose × testing
condition: F(1,22)=0.3, p=0.73; dose: F(1,22)=0.3, p=0.77]
(Table 1).
In order to evaluate the source of these effects of MPH
on trials to criteria, we next examined drug effects on the
proportion of total trials that were completed correctly and
incorrectly in the two learning conditions. For retention
performance, ANOVA detected a main effect of dose on
correct responding in the first four five-trial bins [bin ×
dose: F(1,22)=2.4, p≤0.05; dose: F(1,22)=3.2, p≤0.05] due
to the fact that rats treated with the lower dose of MPH
were overall less accurate than after saline administration
(Fig. 3b). For the reversal sessions, there was also a
significant bin × dose interaction [F(1,22)=13.0, p≤0.001],
without a main effect of dose, for the proportion of trials
completed correctly [F(1,22)=1.7, p=0.20]; MPH increased
correct responding in the last two five-trial bins (Fig. 3b).
Furthermore, no main effect of dose was found for
perseverative responding [F(1,22)=0.1, p=0.87] or for
neutral errors [F(1,22)=1.4, p=0.26], though there was a
significant dose × bin interaction for perseveration [F(1,22)=
2.2, p≤0.05] (Fig. 3c), but not for neutral errors [F(1,22)=
0.5, p=0.87] (data not shown). This resulted from
Fig. 3 a Total number of trials required to reach criteria on retention
and reversal sessions after administration of MPH (0.33–1.0 mg/kg) or
saline (1 ml/kg, SAL). b Effect of MPH or SAL administration on
correct responses (% of total responses) in the first four and five bins
of retention and reversal sessions respectively. c Perseverative
responses (% of total responses) in the first five bins of the reversal
session after saline or MPH. Data are expressed as mean±SEM (n=
23). *p≤0.05, significantly different from saline; **p≤0.01
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decreased perseveration in the final five-trial bins, an effect
specific to the lower dose of MPH (Fig. 3c).
Experiment 2: selective inhibition of the DAT
does not affect performance of the four-choice task
For these studies, the same set of rats (n=23) involved in
the MPH study were used to evaluate the effects of GBR.
As shown in Fig. 4a, the two doses of GBR tested (2.5
and 5 mg/kg) did not affect the total number of trials
required to reach criteria in either the retention or reversal
sessions [testing condition × dose: F(1,22)=0.2, p=0.82;
dose: F(1,22)=1.2, p=0.31]. However, GBR did dose-
dependently increase the number of anticipatory responses
per trial [dose × testing condition: F(1,22)=1.1, p=0.35;
dose: F(1,22)=3.9, p≤0.05]. Post hoc comparisons revealed
that the increase in anticipatory responses was significant
for the higher dose of GBR in the retention session
(t=−2.6, df=22, p≤0.05; Table 1). The latency to initiate a
trial and the pellet retrieval time were not altered by GBR
[dose × testing condition: all F’s<1; dose, respectively:
F(1,22)=1.2, p=0.31, F(1,22)=1.3, p=0.75] (Table 1).
In terms of the effect of GBR on the accuracy in the first
20 trials of the retention session, the ANOVA failed to
reach significance [dose × bin: F(1,22)=0.1, p=0.99; dose:
F(1,22)=2.1, p=0.13] (Fig. 4b). Considering the first five
bins of the reversal session, no effect of GBR was found for
the proportion of total trials completed correctly [dose ×
bin: F(1,22)=1.5, p=0.17; dose: F(1,22)=0.1, p=0.88]
(Fig. 4b), for perseveration [dose × bin: F(1,22)=0.5, p=
0.84; dose: F(1,22)=0.7, p=0.50] (Fig. 4c), or for neutral
errors [dose × bin: F(1,22)=1.8, p=0.08; dose: F(1,22)=0.7,
p=0.53] (data not shown).
Experiment 3: NET inhibitors selectively improve
performance in the reversal sessions
Based upon our preliminary studies using a two-choice task
(Seu and Jentsch 2006), we hypothesized that NET
inhibitors (ATO and DMI) would improve performance of
the four-choice reversal learning task. A priori tests
revealed that both ATO and DMI decreased the total
number of trials required to reach criteria in the reversal
session (ATO: t=1.7, df=21, p≤0.05; DMI: t=2.4, df=15,
p≤0.05), while neither treatment affected the number of
trials to criteria in retention (ATO t=0.8, df=21, p=0.44;
DMI: t=−0.51, df=15, p=0.62; Figs. 5a and 6a). The
ANOVA failed to detect a significant effect of dose on total
trials to criterion for both ATO [F(1,21)=3.3, p=0.08] and
DMI [F(1,15)=2.4, p=0.14]; however, there was a signifi-
cant dose × testing condition interaction for DMI [F(1,15)=
6.3, p≤0.05], but not for ATO [F(1,21)=1.3, p=0.27]. As
shown in Figs. 5b and 6b, ATO and DMI did not affect
correct responding in the first four five-trial bins of the
retention sessions (all F’s<1, ns). In addition, ANOVA
detected only trends for increases in correct responding
in reversal for both NET inhibitors [ATO: F(1,21)=2.7,
p=0.12; DMI: F(1,15)=3.3, p=0.09]; however, there was
a significant dose × bin interaction for DMI [F(1,15)=2.3,
p=0.04], but not for ATO [F(1,21)=1.4, p=0.24] (Figs. 5b
and 6b).
Notably, ANOVA detected a main effect of dose for both
NET inhibitors on perseverative responses during reversal
[ATO: F(1,21)=4.8, p=0.04; DMI: F(1,15)=4.9, p=0.04], as
well as a dose × bin interaction for DMI [F(1,15)=2.4, p=
0.04], but not for ATO [F(1,21)=1.3, p=0.28] (Figs. 5c and
6c). On the other hand, there was no main effect of dose for
Table 1 Effect of MPH, GBR, ATO, and DMI on motor latencies and anticipatory responding
Drug Dose (mg/kg) Mean trial initiation latency (s) Mean pellet retrieval time (s) Tot anticipatory/Tot trials
Retention Reversal Retention Reversal Retention Reversal
MPH 0 3.89±0.49 4.94±0.68 1.34±0.05 1.30±0.03 0.98±0.13 0.99±0.11
0.3 4.06±0.46 4.29±0.42 1.35±0.04 1.26±0.04 1.10±0.17 0.98±0.11
1 4.34±0.45 4.92±0.48 1.34±0.05 1.30±0.03 1.05±0.14 0.93±0.11
GBR 0 3.58±0.52 3.74±0.35 1.36±0.05 1.28±0.04 0.71±0.13 0.78±0.08
2.5 3.69±0.32 3.31±0.29 1.36±0.06 1.30±0.03 0.98±0.16 0.88±0.12
5 3.47±0.40 3.05±0.26 1.33±0.05 1.29±0.04 1.19±0.24* 0.95±0.12
ATO 0 4.52±0.53 4.14±0.41 1.41±0.05 1.36±0.04 1.08±0.15 1.26±0.13
1 4.73±0.56 5.29±0.67 1.44±0.05 1.46±0.05* 1.04±0.13 0.96±0.11
DSI 0 5.70±1.08 7.47±1.90 1.52±0.09 1.44±0.08 1.25±0.29 0.90±0.12
5 8.50±1.89* 9.56±1.45 1.67±0.13* 1.60±0.09** 0.87±0.16 0.75±0.12
Mean trial initiation latency, mean pellet retrieval time, and number of anticipatory response per trial, under retention or reversal condition, are
reported for all pharmacological studies. Trial initiation latency and pellet retrieval time are expressed as mean (in s) of total time ±SEM;
anticipatory responses are expressed as the mean of responses/trials completed ±SEM.
*p≤0.05, significantly different from saline; **p≤0.01
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either of the two drugs on neutral errors [ATO: F(1,21)=
0.04, p=0.85; DMI: F(1,15)=0.06, p=0.81] (data not shown)
nor were there any dose × testing condition interactions
[ATO: F(1,21)=1.5, p=0.21; DMI: F(1,15)=0.9, p=0.50].
As shown in Table 1, the latency to initiate a trial tended
to be affected by ATO [dose × testing condition: F(1,21)=
1.6, p=0.22; dose: F(1,21)=3.1, p=0.09], while for DMI,
there was a main effect of dose [F(1,15)=5.2, p≤0.05] but no
dose × testing condition interaction [F(1,15)=0.1, p=0.78];
further paired comparisons revealed that DMI significantly
increased latency only in the retention sessions (t=−2.1,
df=15, p≤0.05; Table 1). In addition, the time required to
retrieve the reward was affected by both ATO [dose ×
testing condition: F(1,21)=2.8, p=0.11; dose: F(1,21)=4.3,
p≤0.05) and DMI [dose × testing condition: F(1,15)=0.0,
p=0.95; dose: F(1,15)=18.2, p≤0.001]. As shown in Table 1,
ATO increased pellet retrieval time in the reversal sessions
(t=−2.5, df=21, p≤0.05), while DMI exerted effects in both
the retention (t=−2.2, df=15, p≤0.05) and the reversal
sessions (t=−3.4, df=15, p≤0.01). Anticipatory responses
were not affected by ATO [dose × testing condition:
F(1,21)=1.4, p=0.24; dose: F(1,21)=1.9, p=0.17], while there
was a trend for a main effect of dose for DMI [F(1,15)=3.9,
p=0.06] without a significant dose × testing condition
interaction [F(1,15)=0.9, p=0.36] (Table 1).
Monkey studies: effect of MPH and ATO on performance
of a visual discrimination task
The effect of MPH and ATO was also tested in non-human
primates performing a visual discrimination task. Con-
sidering the retention session (data not shown), there was
no main effect of drug treatment for the total number of
errors [F(2,6)=1.5, p=0.3]. ATO did not alter the total
Fig. 5 Effect of ATO (1 mg/kg) or SAL (1 ml/kg) on a total number
of trials to criteria, b on correct, and c perseverative responses (% of
total responses). Data are expressed as mean±SEM (n=22). *p≤0.05,
significantly different from saline
Fig. 4 Effect of GBR (2.5–5 mg/kg) or SAL (1 ml/kg) on a total
number of trials to criteria, b on correct, and c perseverative responses
(% of total responses). Data are expressed as mean±SEM (n=23)
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number of errors in the retention sessions (two-tailed t test:
t=−0.8, df=3, p=0.47), while MPH exerted a very weak
trend to increase the total number of errors (two-tailed
t test: t=−1.8, df=3, p=0.16). Furthermore, none of the
drugs affected the number of errors made during the
retention component given within the reversal sessions
[ANOVA for effect of treatment: F(2,6)=2.3, p=0.4; two-
tailed t tests, ATO: t=−0.7, df=3, p=0.49; MPH: t=−1.2,
df=3, p=0.29] (Fig. 7).
On the other hand, there was a main effect of drug
treatment for perseverative errors when reversal was not
preceded by retention [between session reversal; main
effect of drug: F(2,6)=5.4, p=0.04], while the effect of
treatment on perseverative errors preceded by retention was
at a trend level [within session reversal; F(2,6)=3.8, p=
0.08]. Tests of a priori hypotheses showed that ATO
decreased the number of perseverative errors made by
subjects when reversing the discrimination that was
preceded by a retention test (one-tailed t test: t=2.4, df=3,
p≤0.05; Fig. 7) while not affecting perseveration for the
reversal which was not preceded by a retention test (one-
tailed t test: t=−0.5, df=3, p=0.69; data not shown). The
opposite trend was observed for MPH; the drug did not
significantly affect reversal of the discrimination that was
preceded by a retention test (one-tailed t test: t=1.2, df=3,
p=0.15; Fig. 7) but tended to decrease perseverative errors
when the non-retained discrimination was reversed (one-
tailed t test: t=1.9, df=3, p=0.07; data not shown). Neither
of the drugs tested affected the number of neutral errors
made when reversal followed retention [effect of treatment:
F(2,6)=1.2, p=0.4; two-tailed t tests, ATO: t=1.2, df=3, p=
0.31; MPH: t=1.0, df=3, p=0.36] (Fig. 7) or when it did
not [effect of treatment: F(2,6)=0.9, p=0.5; two-tailed t
tests, ATO: t=−1.2, df=3, p=0.28; MPH: t=−1.2, df=3, p=
0.30] (data not shown).
Discussion
Using a novel four-choice position discrimination task
developed to study behavioral flexibility in rats, we show
that three drugs that inhibit NET with varying degrees of
selectivity—ATO, DMI, and MPH—exerted a common
effect to reduce the total number of trials required to reverse
a learned discrimination; selective inhibition of DAT was
not associated with a similar performance effect. Further-
more, very similar effects of ATO and MPH were found in
monkeys trained to perform a visual discrimination reversal
task.
In the four-choice discrimination task for rats, subjects
were required to either retain or reverse a position–reward
association learnt in the previous session; the difficulty
Fig. 7 Effect of MPH (0.33 mg/kg) or ATO (1 mg/kg) on
performance on the retention or reversal of discrimination set 2 (i.e.,
set of discriminanda that were reversed after a priming retention). For
the retention phase, we report total number of errors, while for the
reversal phase, perseverative and neutral errors are presented
separately. Data are expressed as mean of errors±SEM (n=4). *p≤
0.05, significantly different from saline
Fig. 6 Effect of DMI (5 mg/kg) or SAL (1 ml/kg) on a total number
of trials to criteria, b on correct, and c perseverative responses (% of
total responses). Data are expressed as mean±SEM (n=16). *p≤0.05,
significantly different from saline; **p≤0.01; ***p≤0.001
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associated with switching responses was revealed by the
significantly higher number of trials required to complete
reversal, as opposed to retention, conditions. The dissocia-
tions between retention and reversal performance specifi-
cally arose from the conditioned tendency to respond to the
previously learnt rule; this pre-potent response style
facilitates efficient performance when the rule is unaltered
(retention), while it causes difficulty with switching
position–reward associations (reversal). Notably, rats
appeared to guide their performance according to a set of
long-term reinforcement rules that incorporated information
learned over many sessions because they responded most to
the hole reinforced in the most recent session and least to
the hole reinforced longest in the past (Fig. 2b). In addition,
reversal of a learned discrimination in monkeys was
associated with a specific persistence of responding towards
the previously trained stimulus. Taken together, these data
support the notion that our tasks incorporate an interesting
element of reversal performance which is the need to inhibit
a previously learned response.
Behavioral basis of NET inhibitor effects on reversal
learning
Further evidence that the reversal tasks used measure the
ability to inhibit pre-potent responses stems from the
pharmacological studies. In rats, selective NET inhibitors
specifically reduced the total number of trials required to
complete reversal sessions and tended to increase the
proportion of trials completed correctly in the first stages
of the session while having no measured effect on
performance in retention. Importantly, the effect of NET
inhibitors on total trials required to complete the reversal
session was associated with a specific decrease in the
perseverative responding in the first stage of the session. In
monkeys, ATO specifically decreased perseverative
responses when the subjects were tested for their ability to
change a response after retention (a condition that likely
“primes” the conditioned action); this was contrasted with
the effect of MPH which only decreased perseverative
errors when no retention was given prior to reversal, an
effect that may relate to the ability of MPH to disrupt
retention and, hence, reduce interference from the previ-
ously learned association. These data may suggest that the
effects of the NET inhibitors were mediated by increased
ability to overcome pre-potent responding toward the
previously trained response. Nevertheless, we cannot rule
out of the possibility that these drugs were improving the
ability to overcome learned irrelevance; in both cases, a
similar reduction in perseverative responses would be
expected.
On the other hand, the selective DAT inhibitor GBR
failed to affect retention or reversal performance other than
producing a dose-dependent increase in anticipatory
responses. Accordingly, previous experiments have shown
that the same doses of GBR used in our study increased
premature responses in the five-choice serial reaction time
task (van Gaalen et al. 2006a) and impulsive decision
making in a delayed reward task (van Gaalen et al. 2006b).
Together with our results, this evidence suggests that the
inhibition of DAT may result in disinhibited responding
without affecting other forms of impulsivity such as
perseveration; this is in line with the idea that different
neuronal mechanisms may underlie different forms of
impulsivity (Dalley et al. 2008; Evenden 1999).
The ability of ATO and DMI to improve reversal
performance was also displayed by the lower dose
(0.33 mg/kg) of the stimulant drug MPH, which is known
to inhibit both NET and DAT (Bymaster et al. 2002; Han
and Gu 2006). Interestingly, similar doses of MPH have
been shown to improve response inhibition (Eagle et al.
2007) and other executive functions in rodents (Arnsten and
Dudley 2005; Berridge et al. 2006). Collectively, this dose
range is associated with plasma concentrations very similar
to those produced by clinical dosing in humans. Although
the improvement in reversal learning induced by MPH in
rats and monkeys was associated with a decrease in
perseverative responses, the same dose of MPH was found
to generally negatively affect retention performance, an
effect not found with selective NET inhibitors. While the
improvement in reversal and impairment in retention
caused by MPH could, theoretically, be attributed to a
deficit in the retrieval of the previously learned rule,
making it easier to learn a new response in reversal, this
seems not to be the case in the current study because, in
rats, methylphenidate reduced perseveration only in the last
bins considered (trials 16–25), while one could expect the
effect to occur from the first trials if a deficit in rule
retrieval was the cause.
Another possible explanation for the opposite effects of
MPH on retention and reversal is that the drug generally
increases switching behavior; in fact, it has been shown that
stimulant drugs increase switching behavior in rodents
(Evenden and Robbins 1983). If this effect alone explained
the results, however, we might have expected to observe an
increase in neutral errors, but this was not the case in the
current study.
In contrast to the effects of the 0.33-mg/kg dose, no
difference in performance of either testing condition was
induced by the high dose of MPH. This may result from an
inverted-U dose–response for methylphenidate on cognition
such that low dose of this stimulant improves cognitive
control, while higher doses induce hyperactivity and
cognitive impairment (Berridge et al. 2006; Eagle et al.
2007). In this study, however, the highest dose of MPH did
not produce any impairment, disinhibited responding, or
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hyperactivity, suggesting that an inverted-U dose–response
effect cannot solely account for our results.
Monoamine systems and behavioral flexibility
Recent data using neurochemical depletion or pharmaco-
logical approaches have highlighted a role for the seroto-
nergic system as an important modulator of reversal
learning (Boulougouris et al. 2008; Clarke et al. 2007).
Our results, along with other experimental and clinical
evidence (see below), suggest that the dopaminergic and
noradrenergic systems may also contribute to behavioral
flexibility and cognitive control. For example, pharmaco-
logical or genetic interventions targeting different dopamine
receptor subtypes affect performance in reversal learning or
attention set-shifting paradigms (Floresco et al. 2006;
Izquierdo et al. 2006; Lee et al. 2007; Mehta et al. 2001;
Ragozzino 2002). Additionally, administration of the alpha-
2 adrenergic receptor agonist guanfacine has been shown to
improve reversal learning in aged monkeys (Steere and
Arnsten 1997), while in rodents, stimulus reversals and
extra-dimensional shift were improved by high dose of the
alpha-2 antagonist atipamezole (Lapiz and Morilak 2006).
Furthermore, accumulating evidence suggests that dysfunc-
tions of both the noradrenergic and the dopaminergic
system may contribute to ADHD symptoms, including
impulsivity, inattention, executive dysfunction, and poor
cognitive control and that drugs acting on these systems
may be helpful for the treatment of the disorder (Arnsten
2006; Biederman and Spencer 1999; Frank et al. 2007;
Robbins 2007).
Interestingly, the current study shows that NET inhib-
itors with clinical efficacy in the treatment of ADHD
improve the ability of monkeys and rats to overcome pre-
potent responding. Our results are in accord with recent
studies reporting the beneficial effects of selective and non-
selective NET inhibitors on behavioral inhibition in rodents,
healthy humans, and ADHD subjects (Aron et al. 2003a;
Blondeau and Dellu-Hagedorn 2007; Chamberlain et al.
2007, 2006; Eagle et al. 2007; Navarra et al. 2008;
Robinson et al. 2008).
Pharmacological and neurochemical mechanisms
NET and DAT are expressed on noradrenergic and
dopaminergic terminals, respectively, and their function is
to reuptake norepinephrine or dopamine released in the
extracellular compartment in order to terminate their
synaptic or extra-synaptic actions; therefore, blockade of
NET or DAT results in an increase of extracellular levels of
norepinephrine and dopamine, respectively, and consequent
stimulation of receptors in brain regions receiving projec-
tions from these neurotransmitter systems.
The benefit associated with administration of NET
inhibitors, compared with the absence of relevant effects
of the selective DAT inhibitor, seems to suggest that the
modulation of the noradrenergic system is crucial for the
improvement in behavioral flexibility observed in our
study. However, it is well known that the selective NET
inhibitors are also capable of increasing extracellular
dopamine in specific regions such as the prefrontal cortex
(Berridge et al. 2006; Bymaster et al. 2002; Swanson et al.
2006). In fact, in the prefrontal cortex, a low expression of
DAT (Lammel et al. 2008) indicates that a significant
portion of extracellular dopamine is cleared by NET
(Carboni et al. 2006; Mazei et al. 2002; Moron et al.
2002) which has high affinity for both catecholamines. For
this reason, administration of selective and non-selective
NET inhibitors results in increase of both norepinephrine
and dopamine within the prefrontal cortex (Berridge et al.
2006; Bymaster et al. 2002; Swanson et al. 2006), while
local infusion of selective DAT inhibitors does not
significantly affect extracellular levels of dopamine in the
cortex (Mazei et al. 2002). On the other hand, drugs acting
on DAT, including MPH, increase dopamine in the ventral
and dorsal striatum (Carboni et al. 2006; Kuczenski and
Segal 1997), an action that is not displayed by selective
NET inhibitors (Bymaster et al. 2002), and these neuro-
chemical effects have been related to the abuse liability of
stimulants medications. For these reasons, the modulation
of extracellular levels of both catecholamines in specific
regions such as the prefrontal or orbitofrontal cortex may be
the mechanism by which NET inhibitors improve inhibitory
control and behavioral flexibility.
Conclusion
Conceptually, treatments that enhance executive/cognitive
control over pre-potent responses are emerging as leading
candidate medications for the treatment of an array
externalizing disorders, including ADHD, substance abuse
and dependence, and other forms of impulse control
problems. The extent to which selective inhibitors of the
norepinephrine membrane transporter improve multiple
aspects of inhibitory control over responding (Blondeau
and Dellu-Hagedorn 2007; Chamberlain et al. 2007; Lapiz
et al. 2007; Navarra et al. 2008; Robinson et al. 2008)
underscore their potential in regards to the treatment of
these behavioral disorders. What remain unknown, how-
ever, are the discrete neuronal effects of increased extra-
cellular dopamine and norepinephrine levels that contribute
to these enhancements in inhibitory control. While certain
component processes that contribute to cognitive control,
e.g., working memory maintenance, depend more on
dopamine D1-like receptor signaling (Arnsten et al. 1994;
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Sawaguchi and Goldman-Rakic 1991), recent work also
indicates that D2-like signaling likely plays an important
role in updating central representations and behavior
(Floresco et al. 2006; Lee et al. 2007; Wang et al. 2004),
demonstrating the complex mechanisms by which cate-
cholamine transmitters modulate dissociable aspects of
cognitive and executive functioning. Further work explor-
ing these multifaceted effects of catecholamine transmitters
is clearly needed.
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